From the Boardroom: Venture Debt Financing a Life Sciences Company

May 15, 2013

Veteran life sciences professionals provided an insider’s perspective on key considerations in venture debt financing for a life sciences company.  Our panel of insiders weighed in on important questions, including:

  • When is it the right time?
  • What are the dilution considerations vs. equity financing?
  • What are the complexities associated with syndicated deals?
  • Should venture debt be part of an overall financing strategy?


A wine reception followed, sponsored by Silicon Valley Bank.


Confirmed Speakers included:

  • David Clapper - CEO, Minerva Surgical, Inc.
  • Ron Eastman - Managing Director, Essex Woodlands Health Ventures
  • Caroline Loewy - CFO, Tobira Therapeutics
  • Amy Olson - Senior Finance Attorney, Ropes & Gray LLP
  • Pete Scott - Head of Life Sciences, Silicon Valley Bank

Ropes & Gray Speakers